|
Monday 30th August 2021 |
Text too small? |
Rua Bioscience announces its annual financial results for the 12 months ended 30 June 2021 (FY21). In FY21, Rua's focus has been on building solid foundations for growth – developing the partnerships, places, processes, and people it needs to create a sustainable medicinal cannabis business model.
Rua’s commitment to creating shareholder value has seen it working on two fronts - preparing to enter local and global medicinal cannabis markets by calendar year end 2021 / early 2022 and developing long-term opportunities across the medicinal cannabis value chain.
Outlook
Rua Bioscience is a pharmaceutical company aiming to lead the production of cannabinoid-derived medicines. The Company has a focused and realistic export strategy, with a clear path to revenue and a view extending along the medicinal cannabis value chain. Proceeds from the IPO continue to fund Rua Bioscience's next growth stage, building long-term resilience and accelerating growth.
Please see the links below for details
Rua Bioscience FY21 Annual Results Market Announcement
Financial Results Announcement FY21
Rua Bioscience Limited FY21 Financial Statements
Source: Rua Bioscience Limited
No comments yet
Fonterra announces Mainland Group leadership change
OCA - Oceania announces Director changes as part of Board refresh
AIA - Analyst and media webcast for FY26 interim results
The Warehouse Group confirms leaner operating structure
SML - Synlait provides half year performance update
RYM - Refreshed strategy and new capital management framework
ENS - Clarification of Gina Tuzcet’s status
BGP - 4th Quarter Sales to 25 January 2026
Contact Energy 2026 Half Year Results Presentation
February 2nd Morning Report